Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products …
Biotechnology
IE, Dublin [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 27.46 | 88.10 | 69.12 | |
| Graham Fair Price | -16.21 | 6.07 | 7.24 | |
| PEG | -49.85 | -0.46 | -0.31 | |
| Price/Book | 5.93 | 3.65 | 3.44 | |
| Price/Cash Flow | 554.84 | 358.44 | 54.74 | |
| Prices/Earnings | 27.16 | 31.06 | 24.43 | |
| Price/Sales | 6.61 | 13.06 | 12.25 | |
| Price/FCF | 554.84 | 358.44 | 54.74 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -1.54 | 0.83 | 0.84 | |
| Operating Margin | 7.39 | 0.12 | 0.12 | |
| ROA | -17.25 | 0.02 | 0.02 | |
| ROE | 0.04 | 0.03 | -16.69 | |
| ROIC | 0.03 | 0.02 | -8.73 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.27 | < 0.005 | 12454.96 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.82 | -0.21 | 74.62 | |
| EPS QOQ | -0.80 | -0.68 | 15.14 | |
| FCF QOQ | -0.59 | -0.86 | -46.46 | |
| Revenue QOQ | -0.38 | -0.07 | 81.25 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 281.21 | 292.18 | 3.90 | |
| Days Sales Outstanding (DSO) | 80.44 | 81.45 | 1.26 | |
| Inventory Turnover | 0.32 | 0.31 | -3.76 | |
| Debt/Capitalization | 0.18 | 0.19 | 7.89 | |
| Quick Ratio | 2.44 | 2.31 | -5.32 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 8.14 | 7.47 | -8.20 | |
| Cash | 5.34 | 4.44 | -16.89 | |
| Capex | -0.09 | -0.05 | 42.76 | |
| Free Cash Flow | 0.51 | 0.08 | -85.15 | |
| Revenue | 2.29 | 2.09 | -8.78 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad